| Stage | PFE | % of rev | MRNA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $16.6B | 100.00% | $1.3B | 100.00% | PFE ×12.63 |
| Gross profit | $12.6B | 75.71% | $995M | 75.78% | MRNA +0.1pp |
| Operating income | $3.7B | 22.14% | $130M | 9.90% | PFE +12.2pp |
| Pre-tax income | $3.4B | 20.41% | $171M | 13.02% | PFE +7.4pp |
| Net income | $3.3B | 19.61% | $162M | 12.34% | PFE +7.3pp |
| Stage | PFE | MRNA | Gap · A − B |
|---|---|---|---|
| Revenue | $16.6B100.00% | $1.3B100.00% | PFE ×12.63 |
| Gross profit | 75.71%$12.6B | 75.78%$995M | MRNA +0.1pp |
| Operating income | 22.14%$3.7B | 9.90%$130M | PFE +12.2pp |
| Pre-tax income | 20.41%$3.4B | 13.02%$171M | PFE +7.4pp |
| Net income |
| 19.61%$3.3B |
| 12.34%$162M |
| PFE +7.3pp |
No shared counterparties.